PCR-Based Gastroenteritis Diagnostic Assay Receives European Marketing Approval
By LabMedica International staff writers Posted on 06 Oct 2014 |
Image: Mobidiag’s new Amplidiag product line encompasses innovative multiplex diagnostic tests for gastrointestinal infections (Photo courtesy of Mobidiag).
A PCR-based test that optimizes screening of gastroenteritis-causing bacteria directly from stool samples has been certified for marketing in Europe as a CE-IVD product according to Directive 98/79/EC regarding in vitro diagnostic medical devices.
The Mobidiag Ltd. (Espoo, Finland) Amplidiag Bacterial GE test utilizes well-established qPCR (quantitative polymerase chain reaction) technology for the rapid qualitative detection of eight gastroenteritis-causing bacteria directly from stool samples without requiring pre-culturing of the samples.
Amplidiag Bacterial GE rapidly detects eight of the most common and important enteric bacterial pathogens with a single assay carried out on DNA extracted from the same stool sample and enables same-day reporting of results. In addition to Campylobacter, Salmonella, Shigella/EIEC, and Yersinia, the test also detects the diarrheagenic E. coli strains: enteropathogenic E. coli (EPEC), enteroaggregative E. coli (EAEC), enterohemorrhagic E. coli (EHEC) and enterotoxigenic E. coli (ETEC).
Amplidiag Bacterial GE was validated by assaying 1,235 patient samples and 125 spiked samples in a two-center performance evaluation study conducted in Sweden and Finland. The results showed an overall sensitivity of 99.0% and specificity of 99.9%, when compared with routine stool culture and independent nucleic acid-based methods. Amplidiag Bacterial GE did not give any false negative findings when results were compared with stool culture.
Related Links:
Mobidiag Ltd.
The Mobidiag Ltd. (Espoo, Finland) Amplidiag Bacterial GE test utilizes well-established qPCR (quantitative polymerase chain reaction) technology for the rapid qualitative detection of eight gastroenteritis-causing bacteria directly from stool samples without requiring pre-culturing of the samples.
Amplidiag Bacterial GE rapidly detects eight of the most common and important enteric bacterial pathogens with a single assay carried out on DNA extracted from the same stool sample and enables same-day reporting of results. In addition to Campylobacter, Salmonella, Shigella/EIEC, and Yersinia, the test also detects the diarrheagenic E. coli strains: enteropathogenic E. coli (EPEC), enteroaggregative E. coli (EAEC), enterohemorrhagic E. coli (EHEC) and enterotoxigenic E. coli (ETEC).
Amplidiag Bacterial GE was validated by assaying 1,235 patient samples and 125 spiked samples in a two-center performance evaluation study conducted in Sweden and Finland. The results showed an overall sensitivity of 99.0% and specificity of 99.9%, when compared with routine stool culture and independent nucleic acid-based methods. Amplidiag Bacterial GE did not give any false negative findings when results were compared with stool culture.
Related Links:
Mobidiag Ltd.
Latest Microbiology News
- Integrated Solution Ushers New Era of Automated Tuberculosis Testing
- Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia